Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;4(3):110-6.
doi: 10.1177/2045125313511487.

Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

Imran B Chaudhry  1 , Nusrat Husain  1 , Richard Drake  1 , Graham Dunn  1 , M Omair Husain  2 , Ajmal Kazmi  3 , Munir M Hamirani  4 , Raza Rahman  5 , John Stirling  1 , William Deakin  1
Affiliations

Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study

Imran B Chaudhry et al. Ther Adv Psychopharmacol. 2014 Jun.

Abstract

Objectives: There is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. Statins are cholesterol-lowering agents but have been found to be anti-inflammatory and also decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3) receptor antagonist widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer. Small studies have suggested that adjunctive ondansetron is efficacious against schizophrenia symptoms. We carried out a feasibility study in schizophrenia patients (within 5 years of first diagnosis) to explore the adjunctive use of simvastatin and ondansetron on positive, negative and general psychopathology.

Methods: This was a 12-week rater-blind placebo-controlled study. A total of 36 patients with DSM-IV diagnosis of schizophrenia were recruited, 12 in each arm. Patients were assessed at baseline and at 12 weeks using Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) scale, Global Assessment of Functioning (GAF) and Abnormal Involuntary Movement Scale (AIMS).

Results: Both simvastatin and ondansetron provide some evidence of a reduction in symptoms compared with treatment as usual (TAU) on PANSS total score, although this was not statistically significant. In the secondary analyses, no significant differences were seen on CGI, GAF and AIMS.

Conclusions: Anti-inflammatory treatments have been shown to have some beneficial effects in schizophrenia. Both simvastatin and ondansetron provide some evidence of a reduction in symptoms compared with TAU. This study has led to a larger Stanley Medical Research Institute (SMRI)-funded, double-blind, randomized control trial.

Keywords: Psychosis; anti-inflammatory; ondansetron; schizophrenia; simvastatin.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author declares that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Consort flowchart.
See this image and copyright information in PMC

References

    1. Akhondzadeh S., Mohammadi N., Noroozian M., Karamghadiri N., Ghoreishi A., Jamshidi A.H., et al. . (2009) Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res 107: 206–212 - PubMed
    1. Akhondzadeh S., Rezaei F., Larijani B., Nejatisafa A., Kashani L., Abbasi S. (2006) Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia. Schizophr Res 84: 405–410 - PubMed
    1. British National Formulary (BNF) (2012). British Medical Association, Royal Pharmaceutical Society of Great Britain, Edited by Joint Formulary Committee.
    1. Castilla G., Del Carmen Fernandez M., Lopez Chozas J., Jimenez H. (2008) Statins in stroke prevention: what an internist should know. Eur J Intern Med 19: 8–14 - PubMed
    1. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93: 261-265 - PubMed